دورية أكاديمية

Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment.

التفاصيل البيبلوغرافية
العنوان: Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line Treatment.
المؤلفون: Andreatos, Nikolaos, McGarrah, Patrick W., Sonbol, Mohamad Bassam, Starr, Jason S., Capdevila, Jaume, Sorbye, Halfdan, Halfdanarson, Thorvardur R.
المصدر: Current Oncology Reports; Oct2023, Vol. 25 Issue 10, p1127-1139, 13p
مستخلص: Purpose of Review: Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare, aggressive malignancy that can arise from any organ and frequently presents with distant metastases. Advanced disease has a poor prognosis with median overall survival (OS) rarely exceeding 1 year even with systemic therapy. The management paradigm of advanced/metastatic EP-NEC has been extrapolated from small cell lung cancer (SCLC) and commonly consists of 1st line therapy with etoposide and platinum (cisplatin or carboplatin), followed by alternative cytotoxic regimens at the time of progression. Only a minority of patients are able to receive 2nd line therapy, and cytotoxics derived from the SCLC paradigm such as topotecan or lurbinectedin have very limited activity. We aimed to evaluate emerging therapeutic options in the 2nd and later lines and survey potential future developments in this space. Recent Findings: After a long period of stagnation in treatment options and outcomes, more promising regimens are gradually being utilized in the 2nd line setting including systemic therapy combinations such as FOLFIRI, FOLFOX, modified FOLFIRINOX, CAPTEM, and, more recently, novel checkpoint inhibitors such as nivolumab and ipilimumab. Simultaneously, advances in the understanding of disease biology are helping to refine patient selection and identify commonalities between NEC and their sites of origin which may eventually lead to additional targeted therapy options. Summary: While many questions remain, contemporary developments give grounds for optimism that improved outcomes for EP-NEC will soon be within reach. [ABSTRACT FROM AUTHOR]
Copyright of Current Oncology Reports is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:15233790
DOI:10.1007/s11912-023-01438-w